Sanofi can produce millions of doses of hydroxycholoroquine

Sanofi will be able to produce millions of doses of hydroxychloroquine if the results of ongoing clinical trials confirm its effectiveness against Covid-19, the disease caused by the new coronavirus that appeared in China last December, said Thursday the director general of the French pharmaceutical laboratory at Reuters.

Read also: Chloroquine: the dangers of self-medication

Paul Hudson, who took office last September, said the group was currently working at more than 93% of its production capacity.

He explained that Sanofi had chosen to “ overproduce ” this drug in order to supply hospitals in Europe and the United States overwhelmed by the number of patients suffering from the disease seriously. Sanofi has 73 industrial sites in 32 countries.